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Sunlmary 
Tumor necrosis factor o~ (TNF-a) is a multifunctional cytokine that has an important role in 
the pathogenesis of inflammation, cachexia, and septic shock. Although TNF-c~ is mainly produced 
by macrophages, there is evidence regarding TNF-a  production by cells that are not derived 
from bone marrow. TNF-oL production by normal and inflamed human liver was assessed at 
both mRNA and protein levels. Using a wide panel of novel anti-TNF-o~ monoclonal antibodies 
and a specific polyclonal antiserum, TNF-a immunoreactivity was found in hepatocytes from 
patients chronically infected with either hepatitis B virus (HBV) or hepatitis C virus. Minimal 
TNF-a immunoreactivity was detected in the mononuclear cell infiltrate and Kupffer cells. In 
situ hybridization experiments using a TNF-a KNA probe showed a significant expression of 
TNF-o~ mR.NA in hepatocytes, Kupffer cells, and some infiltrating mononuclear cells. By contrast, 
TNF-c~ was detected at low levels in liver biopsies from normal individuals or patients with 
alcoholic liver disease and low expression of TNF-a mKNA was observed in these specimens. 
Transfection of HepG2 hepatoblastoma cells with either HBV genome or HBV X gene resulted 
in induction of TNF-a  expression. Our results demonstrate that viral infection induces, both 
in vivo and in vitro, TNF-o~ production in hepatocytes, and indicate that the HBV X  protein 
may regulate the expression of this cytokine. These findings suggest that TNF-ol may have an 
important role in human liver diseases induced by viruses. 
T 
NF-ol is a multifunctional cytokine that appears to have 
an important role in the pathogenesis of tissue damage 
seen in multiple unrelated conditions such as malaria, chronic 
heart failure, GVHD, septic shock, and cachexia associated 
to malignant and infectious diseases (1). The main stimulus 
for TNF-c~ production appears  to be bacterial LPS.  How- 
ever, other various agents such as parasites,  exotoxins, lym- 
phokines, and malignant cells are also capable  of inducing 
the synthesis of this cytokine (1). Although TNF-a is mainly 
produced by macrophages, this cytokine is also synthesized 
by NK cells or T lymphocytes stimulated through the CD3, 
CD2, or CD69 molecular pathways (2-4). TNF-ol synthesis 
has also been observed in certain L929 fibrosarcoma cells and 
some nonhematopoietic cell lines (5, 6). In addition, TNF-o~ 
is produced by thymic mast cells, keratinocytes, as well as 
myocardial and islet cells  (7-9).  However, it has not been 
established whether or not TNF-a is produced by hepatocytes. 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are 
the main causative agents of chronic viral hepatitis in humans. 
These viruses are capable of infecting hepatocytes, inducing 
inflammatory and necrotic changes in the liver. Since HBV 
is not cytolytic for hepatocytes, the liver damage seen in chronic 
HBV infection appears to be mainly mediated by the immune 
response against the virus (10,  11). CTLs appear to play an 
important role in the liver damage seen in HBV infection 
(12), and cytokines produced by immune cells, such as TNF-ol, 
might also have a role in the liver damage induced by viruses. 
The liver appears  to be a source of several proinflammatory 
cytokines such as IL-1, IL-6, and TNF-ol (13-14), however, 
it has not been determined which liver cells are capable of 
synthesizing these cytokines. In this work, the production 
of TNF-a by normal and inflamed liver was assessed at pro- 
tein and mRNA levels. We have found significant TNF-o~ 
production in liver from patients with chronic HBV and HCV 
infections. It is interesting to note that hepatocytes appear 
to be the main source of TNF-c~ in these conditions. 
Materials  and Methods 
Antibodies and Epitope Mapping Analysis.  The generation of the 
anti-TNF-o~ mAb used in this study has previously been described 
(2, 3). The anti-TNF-ol WI-AT-4 mAb was obtained from Pierce 
Chemical Co. (Rockford, IL). A purified polyclonal anti-TNF-c~ 
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Volume 179  March  1994  841-848 Figure  1.  Immunoprecipitation  of re- 
combinant  12SI-TNF-c~  by different anti- 
TNF-ot mAbs. Precipitation  with the nega- 
tive (P3X63) and positive (WI-AT-4)  con- 
trol mAb is also shown (lanes 15 and 16, 
respectively). Immunocomplexes  were iso- 
lated, and reduced samples were subjected 
to SDS-15% PAGE and autoradiography. 
Lane 1: AM918 mAb; lane 2:AM917 mAb; 
lane 3:AM915  mAb;  lanes 4 and 5:  no 
mAb; lane 6:AM933 mAb; lane 7:AM914 
mAb; lane 8:AM913 mAb; lane 9:AM912 
mAb;  lane 10:AM911  mAb;  lane 11: 
AM939 mAb; lane 12:AM909 mAb; lane 
13:AM908  mAb;  and lane I4:AM903 
mAb. 
antibody developed in sheep was kindly provided by Dr. D. Pascual- 
Salcedo (Hospital La Paz, Madrid, Spain). Epitopes recognized by 
the anti-TNF-c~ mAb were determined by cross-blocking binding 
assays, as described  (15). 
Radiolabelin~ Immunoprecipitation, and Electrophoresis.  The speci- 
ficity of mAb for TNF-ot was confirmed by immunoprecipitation, 
as described (2). Briefly, rTNF-c~ was radioiodinated and mixed with 
mAb-containing culture supernatants. Immunocomplexes were iso- 
lated by the addition of 187.1 rat anti-mouse K chain mAb, fol- 
lowed by protein A from Staphylococcus aureus coupled to Sepharose 
(Pharmacia, Uppsala, Sweden).  Immunoprecipitates were processed 
as previously described  (2),  and  samples were subjected  to  15% 
SDS-PAGE and  autoradiography. 
Patients and Controls.  The study included 20 patients who had 
liver biopsy findings compatible, by internationally accepted criteria 
(16), with chronic active hepatitis,  10 type B and 10 type C. Five 
patients with biopsy-proven alcoholic liver disease and four patients 
with histologically normal liver were studied as controls. All were 
negative for HBsAg and  anti-HCV  antibodies. 
Liver Biopsies.  After written consent, percutaneous liver biop- 
sies were obtained from all patients.  Normal liver biopsies were 
obtained, after written consent,  from patients who underwent  a 
laparotomy for noncomplicated cholecystectomy. A portion of the 
biopsies was fixed in 10% formaldehyde and embedded in paraffin 
by routine methods. Another portion of the biopsies was snap frozen 
in  nitrogen-cooled isopentane  and  stored at  -80~  until  use. 
Immunochemical Staining.  Frozen liver sections (4-6/zm) fixed 
in cold acetone were incubated with  the anti-TNF-c~  mAb.  The 
indirect  immunoperoxidase and the APAAP staining  techniques 
were performed as previously described  (17-19).  In all experiments, 
P3X63 myeloma culture supernatants, as well as several other mAbs 
(17-19)  were used  as controls. 
For immunofluorescence studies,  frozen liver sections were in- 
cubated with a biotinylated polyclonal sheep anti-TNF-ot antiserum. 
After washing three times with Tris-buffered saline,  the sections 
were incubated with an FITC-labeled avidin (Vector Laboratories, 
Inc., Burlingame, CA).  Subsequently,  sections  were washed and 
cell nuclei were counterstained with 4'-6-diamino-2-phenylindole 
(DAPI). Negative controls included both preimmune serum and 
an irrelevant  sheep anti-digoxigenin antiserum (Boehringer Mann- 
helm,  Mannheim,  Germany). 
RNA Probes.  Plasmid pGEM-hTNF-oe (20) were used as tem- 
plates  to generate digoxigenin-labeled  sense  and antisense RNA 
probes (21). A 550-bp fragment of the rat serum albumin cDNA 
was used as positive control for hybridization  on hepatocytes. 
In  Situ  Hybridization.  Paraffin-embedded  liver  sections  were 
dewaxed with bio-clear (Bio-Optica, Milan, Italy), digested 12 min 
with 20/lg/ml proteinase K (Sigma Chemical Co., St. Louis, MO), 
and hybridized overnight at 45~  with a preheated (75~  5 min) 
hybridization  mixture (100 ng/ml of RNA probe, 2x  SSC,  0.5 
mg/ml yeast tRNA, 10 mM dithiothreitol, 50% formamide, 10% 
SDS,  and  20  mM  Tris  HC1,  pH  7.5),  as described  (21).  After 
posthybridization washings in 50% formamide, 5 x  SSC, and 10% 
SDS at 55~  sections  were incubated for 30 min at room temper- 
ature with a mouse anti-digoxigenin mAb (Boehringer  Mannheim). 
Sections  were then washed and stained by the APAAP technique, 
as described above. Negative (TNF-ce sense RNA probe) and posi- 
tive (antisense albumin RNA probe) controls were run simultane- 
ously with  the TNF-o~  antisense RNA probe. 
Transfection of HepG2  Cells.  HepG2 cells were transfected by 
the calcium phosphate precipitation  method.  Transient transfec- 
tions were carried out employing the recircularized whole genome 
of HBV (22),  as well as the plasmid pSBDR-X, which  contains 
the open reading frame of HBV X  gene under the transcription 
control of its own promoter and enhancer (kindly provided by Dr. 
A. Siddiqui,  University of Colorado, Denver, CO). An irrelevant 
plasmid (pAIMI-neo containing the open reading frame of CD69/ 
AIM) was used as negative control. Transfected  HepG2 cells were 
grown on glass coverslips and cells fixed in methanol/acetone. Im- 
munodetection  of  TNF-oe  was  carried  out  by  indirect  im- 
munofluorescence  staining  using  both  anti-TNF-oe  mAb  and  a 
specific anti-TNF-oe polyclonal antiserum.  An anti vascular cell adhe- 
Figure 2.  Immunohistochemical detection of TNF-~ in liver sections. (A-D) Immunoperoxidase staining of liver sections from a patient with chronic 
active hepatitis C (A), alcoholic liver damage (C), and a control individual (B). The negative control (P3X63 myeloma supernatant) ofimmunoperoxidase 
staining is also shown (D). All images correspond to liver sections run at the same time. Sections were counterstained with Carazzi's hematoxylin. 
Original magnifications at 400 (A, C, D) and 200 (B). (E-F) Immunofluorescence staining of liver sections from a patient with chronic active hepatitis 
C with a polyclonal anti-TNF-ot antiserum. To show the presence of cellular infiltrate, cell nuclei were counterstained with DAPI (blue fluorescence) 
in F.  Cell infiltrate shows minimal TNF-~ immunoreactivity  (green fluorescence). Original  magnification at 600. 
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intercellular adhesion molecule 1 (ICAM-1) mAb was used as a 
positive control (23). The 2.2.15 cell line, which is a stably trans- 
fected derivative of HepG2 cells developed by transfection with a 
dimerized  HBV genome (22), was also tested  for TNF-c~ im- 
munoreactivity. 
Results and Discussion 
TNF-ot is mainly produced by macrophages; however, there 
is evidence regarding TNF-ot production by cells that are not 
derived from bone marrow (5-8).  The constitutive activity 
of the TNF-ot gene promoter is canceled in nonmacrophage 
cell lines,  but an as yet unidentified cell factor appears to be 
capable of overcoming this suppressive state (24).  This ap- 
pears to be the mechanism that accounts for the TNF-et syn- 
thesis by some nonhematopoietic cells (5-7).  In this study, 
we  addressed  the  production  of TNF-~  by  normal  and 
inflamed human liver, specifically, the synthesis of this cytokine 
by vitally infected hepatocytes. 
To investigate the possible production of TNF-ot in normal 
and inflamed liver,  we generated a panel of TNF-ot-reactive 
mAbs. These mAbs were found to be specific for three different 
antigenic determinants of TNF-c~: epitopes A (two mAbs), 
B (seven mAbs), and C (three mAbs). All these mAbs selec- 
tively immunoprecipitated the same 17-kD form of TNF-ol 
recognized by control anti-TNF-o~ mAb (Fig.  1). With this 
panel of mAbs, a high level of TNF-ot immunoreactivity was 
detected on liver sections from patients with chronic HBV 
and HCV infections. Such reactivity was observed using anti- 
TNF-o~ mAbs specific for epitope B, but not with those specific 
for A or C  epitopes. TNF-ot immunoreactivity was mainly 
observed in hepatocytes, showing a predominant cytoplasmic 
staining (Fig. 2 A). In most cases, all hepatocytes were diffusely 
stained, but in some cases, the strong reactivity was mainly 
located to the periportal areas, specifically where inflamma- 
tion and piecemeal necrosis was more evident. A weak TNF-ot 
immunoreactivity was observed in some infiltrating cells, with 
no staining  of Kupffer cells.  These results were confirmed 
using a specific polyclonal anti-TNF-ot antiserum (Fig.  2, E 
and t7). The staining pattern obtained in liver sections using 
anti-TNF-ot mAb was clearly different from those obtained 
with other mAbs (11, 18, 19, and data not shown). In addi- 
tion, no staining was obtained with the P3X63 myeloma su- 
pernatant  (Fig.  2 D). 
A low level of TNF-ot immunoreactivity was observed in 
cells from normal  liver  sections (Fig.  2 B).  In these cases, 
a significant  staining was detected in some hepatocytes lo- 
cated to perivenular areas, whereas in other sites, only scat- 
tered positive hepatocytes were found. No apparent TNF-ot 
expression was detected on Kupffer cells. Liver sections from 
alcoholic hepatitis  showed a pattern  of TNF-a  expression 
similar to that found in normal liver (Fig. 2 C). TNF-ot im- 
munoreactivity was mainly located in the cytoplasm,  sug- 
gesting accumulation of the protein into the cells. It is pos- 
sible  that  TNF-ot  is  processed by  a  different  pathway  in 
hepatocytes than  in macrophages  or T  lymphocytes (2,  4, 
25). Thus,  the hepatocyte-derived TNF-ot might not be ac- 
tively secreted, exerting  their actions predominantly in the 
same cell that is producing, or in the neighboring cells. On 
these conditions, no endocrine effects of hepatocyte-derived 
TNF-c~ should be expected. 
Immunohistochemical  studies were confirmed by immu- 
noblotting analysis of liver homogenates using a specific poly- 
clonal antiserum.  These analyses  revealed the presence of a 
specific band of 17 kD in immunoprecipitates from livers with 
HBV infection (data not shown). The above results demon- 
strated the presence of immunoreactive TNF-ot molecules in 
hepatocytes,  with  a  remarkable  upregulated  expression  in 
chronic viral hepatitis. 
In situ hybridization  experiments  using a specific  RNA 
probe revealed  the presence of high  TNF-a  mRNA levels 
in liver sections from both chronic HBV and HCV infec- 
tions. A strong expression of TNF-er mRNA was observed 
in hepatocytes (Fig. 3 A), with a pattern that resembled that 
obtained in immunostaining experiments using anti-TNF-a 
mAb. Positive cells for TNF-ot mRNA were also found in 
the mononuclear cell infiltrate (Fig.  3, D  and F), a finding 
that contrasted with the very low TNF-ot immunoreactivity 
of these cells (Fig.  2, A  and 17). Positive cells with a location 
and morphology of Kupffer cells were found in all cases (Fig. 
3, E  and F).  Low levels of TNF-ot mRNA were detected 
in liver sections from alcoholic liver disease  (Fig.  3 G).  In 
these specimens, the TNF-ot mRNA-expressing  cells were 
also mainly hepatocytes. In normal liver sections,  scattered 
positive hepatocytes were found (Fig. 3 H), whereas Kupffer 
cells were usually negative. 
It has been described that HBV is capable of upregulating 
the expression of ICAM-1 and HLA-DR on hepatocytes (23, 
26). This effect appears to be mediated by the HBV protein 
X that transactivate gene promoters containing nuclear factor 
(NF) KB and other sequence motifs (23, 26). It is conceivable 
that TNF-c~ synthesis by hepatocytes may also be modulated 
by viral proteins,  such as HBV protein X. The presence of 
NF-rB responsive sequences in the TNF-ot gene (27), fur- 
ther supports this point. To test this possibility, we performed 
transfection  experiments on HepG2 cells using both the whole 
HBV genome and the HBV X gene. HepG2 cells transiently 
transfected with either HBV whole genome or HBV X gene, 
showed strong TNF-o~ immunoreactivity (Fig. 4 A, and data 
not shown).  TNF-ot staining was mainly cytoplasmic, but 
cell membrane immunoreactivity was also seen. Untransfected 
HepG2 cells or those transfected with the negative control 
plasmid (pAIMI-neo),  did not show TNF-ct immunoreac- 
Figure  3.  In situ detection  of TNF-a mRNA using a nonradioactive  RNA probe. An enzyme-linked  color  reaction (fast red) identifies  cells  hybridizing 
to the digoxigenin-ll-UTP-labeled TNF-ot probe. All images correspond to the same experiment and were run simultaneously. Antisense probe in 
a liver section from a patient with chronic active hepatitis C (.4, C, D, E, and F). Negative control (sense probe) in a liver section from the same 
biopsy (B). Original magnifications at 200 (.4 and B), 400 (C and D), and 600 (E and F). (G-H) Antisense probe in a liver section from a patient 
with alcoholic liver disease (G) and in a normal liver section (H). Original magnification at 400. 
845  Gonz~lez-Amaro  et al. Figure  4.  Detection  of TNF-(x in hepatoblastoma  HepG2 cells by indirect  immunofluorescence.  (A) Cells transiently  transfected  with whole HBV 
genome and stained  with the anti-TNF  AM918 mAb. (B) Cells transiently  transfected  with a negative  control plasmid (pAIMI-neo) and stained  with 
the anti-TNF AM918 mAb. (C) Hep.G2 cells stably transfected  with dimerized  HBV genome  (cell line 2.2.15) stained  with the anti-TNF-~x  AM918 
mAb. (D) Cells stably transfected  with dimerized HBV genome and stained with an anti-ICAM-1 mAb. 
tivity (Fig.  4 B, and data not shown).  These results were 
confirmed with the 2.2.15  cell line,  stably transfected with 
dimerized HBV genome. These cells also showed TNF-ol im- 
munoreactivity with both anti-TNF-ot mAb and a specific 
polyclonal antiserum (Fig. 4 C, and data not shown). As has 
been described (23), HepG2 cells transfected with HBV ge- 
nome or HBV X  gene, showed a significant ICAM-1 im- 
munoreactivity (Fig. 4 D). ICAM-1 was mainly located to 
the cell membrane (Fig.  4 D), with a staining pattern that 
contrasted with that obtained with anti-TNF-a mAb. 
Since TNF-ol production was detected, at low levels, in 
hepatocytes from individuals with no evidence of hepatic viral 
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infection, stimulus for hepatocytes TNF-o~ production, other 
than viral proteins, must exist. 
TNF-o~ appears  to play a role in the tissue damage seen 
in conditions in which inflammation and liver necrosis occur, 
such as GVHD and liver allograft rejection (28,  29). Large 
quantities of TNF-o~ may have a deleterious local effect in 
HBV and HCV liver infection through several mechanisms. 
TNF-o~ may participate in the increased  liver expression  of 
ICAM-1 and other adhesion receptors in both HBV and HCV 
liver infection (18, 19), contributing to the inflammatory  and 
cytotoxic phenomena seen in these conditions. TNF-c~ might 
be cytotoxic itself, and in addition, it might participate in the activation of cytotoxic immune cells. TNF-a also might 
induce HBV and HCV viral replication, as in the case of HIV 
(30). The possible autocrine induction (via TNF-oe) of large 
quantities of nitric oxide synthesis by hepatocytes (31) is an- 
other interesting possibility. 
Our results demonstrate for the first time the in vivo produc- 
tion of TNF-o~ by human hepatocytes, with a remarkable 
upregulation in HCV and HBV infection. The constitutive 
production of TNF-c~ by nonhemopoietic cells may have an 
important role in the normal physiology of several tissues, 
including the liver. Under abnormal circumstances, such as 
viral infections, an increased production of TNF-ol by non- 
hemopoietic cells might be deleterious and mediate tissue 
damage. Local production of TNF-oe by nonimmune cells 
may have an important role in tissue inflammation and necrosis 
seen in infectious and autoimmune diseases. 
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